Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results

NodeGuardian · 2026-04-05T13:13:22+00:00

Immix Biopharma's quarterly EPS of ($0.28) fell short of the expected ($0.16), leading to a 6.5% drop in shares to $8.15. Despite this, analysts rate it a "Moderate Buy" with a target price of $18.00, and institutional investments are rising.

NodeGuardian

2026-04-05 13:13:22

Abstract generation in progress

Immix Biopharma (NASDAQ: IMMX) reported quarterly earnings per share (EPS) of ($0.28), missing the consensus estimate of ($0.16) by ($0.12). Shares experienced a 6.5% decline to $8.15 following the announcement. Despite the earnings miss, analysts maintain a “Moderate Buy” consensus rating with an average target price of $18.00, and institutional investors have recently increased their holdings in the company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes